TY  - BOOK
AU  - Gara, Naveen
TI  - What the infectious disease physician needs to know about pegylated interferon and ribavirin. [Review]
SN  - 1058-4838
KW  - *Antiviral Agents/pk [Pharmacokinetics]
KW  - *Hepatitis C, Chronic/dt [Drug Therapy]
KW  - *Hepatitis C, Chronic/me [Metabolism]
KW  - *Interferons/pk [Pharmacokinetics]
KW  - *Polyethylene Glycols/pk [Pharmacokinetics]
KW  - *Ribavirin/pk [Pharmacokinetics]
KW  - Antiviral Agents/ae [Adverse Effects]
KW  - Humans
KW  - Infectious Disease Medicine
KW  - Interferons/ae [Adverse Effects]
KW  - Polyethylene Glycols/ae [Adverse Effects]
KW  - Ribavirin/ae [Adverse Effects]
KW  - MedStar Washington Hospital Center
KW  - Medicine/Gastroenterology
KW  - Journal Article
KW  - Research Support, N.I.H., Extramural
KW  - Research Support, N.I.H., Intramural
KW  - Review
N1  - Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007
N2  - The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed
UR  - http://dx.doi.org/10.1093/cid/cit074
ER  -